Literature DB >> 20164568

Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.

Xuesong Chen1, Othman Ghribi, Jonathan D Geiger.   

Abstract

Sporadic Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases and as such they represent major public health problems. Finding effective treatments for AD and PD represents an unmet and elusive goal largely because these diseases are chronic and progressive, and have a complicated and ill-understood pathogenesis. Although the underlying mechanisms are not fully understood, caffeine, the most commonly ingested psychoactive drug in the world, has been shown in human and animal studies to be protective against AD and PD. One mechanism implicated in the pathogenesis of AD and PD is blood-brain barrier (BBB) dysfunction and we reported recently that caffeine exerts protective effects against AD and PD at least in part by keeping the BBB intact. The present review focuses on the role of BBB dysfunction in the pathogenesis of AD and PD, caffeine's protective effects against AD and PD, and potential mechanisms whereby caffeine protects against BBB leakage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164568      PMCID: PMC3086010          DOI: 10.3233/JAD-2010-1376

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  211 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Authors:  Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 3.  Cerebral microvascular pathology in aging and Alzheimer's disease.

Authors:  E Farkas; P G Luiten
Journal:  Prog Neurobiol       Date:  2001-08       Impact factor: 11.685

Review 4.  Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Authors:  Rashid Deane; Berislav V Zlokovic
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

5.  Impaired functional recovery after stroke in the stroke-prone spontaneously hypertensive rat.

Authors:  J K McGill; L Gallagher; H V O Carswell; E A Irving; A F Dominiczak; I M Macrae
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

6.  Possible involvement of phosphorylation of occludin in tight junction formation.

Authors:  A Sakakibara; M Furuse; M Saitou; Y Ando-Akatsuka; S Tsukita
Journal:  J Cell Biol       Date:  1997-06-16       Impact factor: 10.539

7.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors:  Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

8.  Beta-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain.

Authors:  Ibolya G Farkas; Andrea Czigner; Eszter Farkas; Endre Dobó; Katalin Soós; Botond Penke; Valéria Endrész; András Mihály
Journal:  Acta Histochem       Date:  2003       Impact factor: 2.479

9.  Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.

Authors:  G L Bowman; J A Kaye; M Moore; D Waichunas; N E Carlson; J F Quinn
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

10.  The integrity of the blood-brain barrier in Alzheimer's disease.

Authors:  A Algotsson; B Winblad
Journal:  Acta Neurol Scand       Date:  2007-06       Impact factor: 3.209

View more
  42 in total

1.  Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Authors:  Hisham Qosa; Alaa H Abuznait; Ronald A Hill; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

3.  Human brain endothelial cells are responsive to adenosine receptor activation.

Authors:  Jeffrey H Mills; Leah Alabanza; Babette B Weksler; Pierre-Olivier Couraud; Ignacio A Romero; Margaret S Bynoe
Journal:  Purinergic Signal       Date:  2011-02-17       Impact factor: 3.765

4.  Effect of mouse strain as a background for Alzheimer's disease models on the clearance of amyloid-β.

Authors:  Hisham Qosa; Amal Kaddoumi
Journal:  J Syst Integr Neurosci       Date:  2016-04-30

5.  Age Modulates the Association of Caffeine Intake With Cognition and With Gray Matter in Elderly Diabetics.

Authors:  Rebecca K West; Ramit Ravona-Springer; Abigail Livny; Anthony Heymann; Danit Shahar; Derek Leroith; Rachel Preiss; Ruth Zukran; Jeremy M Silverman; Michal Schnaider-Beeri
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-04-23       Impact factor: 6.053

Review 6.  Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.

Authors:  F Panza; V Solfrizzi; M R Barulli; C Bonfiglio; V Guerra; A Osella; D Seripa; C Sabbà; A Pilotto; G Logroscino
Journal:  J Nutr Health Aging       Date:  2015-03       Impact factor: 4.075

Review 7.  The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Authors:  Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2012-04-11       Impact factor: 4.077

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

9.  Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease.

Authors:  Fatma M Ghoneim; Hanaa A Khalaf; Ayman Z Elsamanoudy; Salwa M Abo El-Khair; Ahmed M N Helaly; El-Hassanin M Mahmoud; Saad H Elshafey
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 10.  Craving espresso: the dialetics in classifying caffeine as an abuse drug.

Authors:  Max Kenedy Felix Dos Santos; Elaine C Gavioli; Lorena Santa Rosa; Vanessa de Paula Soares-Rachetti; Bruno Lobão-Soares
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-18       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.